Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.Tokyo, Japan, Aug 26, 2005 - (JCN JCN - Jane's Combat Network JCN - Japan Corporate News JCN - Jewish Congregational Network JCN - Job Control Number JCN - joint communications network (US DoD) JCN - Journal of Cardiovascular Nursing JCN - Journal of Child Neurology JCN - Journal of Christian Nursing JCN - Journal of Cognitive Neuroscience neu·ro·sci·ence (n  r  -s JCN - Journal on Communications Networks (IEEE Communications Society) Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and BioArctic Neuroscience Inc. (Headquarter: Uppsala Uppsala (ŭp`sələ, –sä'lä), city (1990 pop. 109,500), capital of Uppsala co., E Sweden, on the Fyrisån River. It is an industrial and cultural center and a railroad junction. Manufactures include machinery, printed materials, processed food, clothing, pharmaceuticals, and footwear., Sweden, CEO: Par Gellerfors) announced today that on August 24, they signed a strategic alliance agreement to develop an immunotherapy im mu·no·thera·peu tic (-py for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia.. Based on this agreement, Eisai will obtain first right of refusal for drug candidates developed resulting from the research. BioArctic Neuroscience Inc. is a biotech company that was established in January, 2003, with the aim of industrial application of Alzheimer's disease research by Prof. Lannfelt, Uppsala University, who is an internationally well-known Alzheimer's disease researcher. Currently, Prof. Lannfelt's group is conducting basic research to further advance knowledge about the Arctic mutation of A, for immunotherapy in Alzheimer's disease. Arctic mutation of A is a mutation discovered by Prof. Lannfelt in 2001. It causes familial Alzheimer's disease and pathophysiologically shows very similar lesions to those found in non-familial Alzheimer's disease familial Alzheimer's disease n. . In this respect, Arctic mutation of Ais expected to be applied to evaluate efficacy in a wide range of Alzheimer's disease treatment. The research will be carried out mainly by BioArctic Neuroscience and Prof. Lannfelt. An inherited form of Alzheimer's disease caused by a defect on a particular chromosome. Eisai actively puruses Purus (p  rz`), river, c.2,100 mi (3,380 km) long, rising in the Andes Mts., E Peru. It flows generally northeast in a meandering course, across Acre and Amazonas states, NW Brazil, to the Amazon River. alliances with outside organizations in order to expand its product line-up in the neurology arena, one of the company's franchise areas. With the BioArctic Neuroscience agreement, Eisai wishes to gain a new immunotherapy in drug treatment of Alzheimer's disease cut out by Aricept Ar·i·cept (âr -s pt, and lead to a novel, beneficial treatment for Alzheimer's disease. Contacts: Copyright [c] 2005 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion